Antiglutamatergic Therapy to Protect the Immature Brain Against Nerve Agents
抗谷氨酸治疗可保护未成熟的大脑免受神经毒剂的侵害
基本信息
- 批准号:9769166
- 负责人:
- 金额:$ 44.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AMPA ReceptorsAcademyAcetylcholineAcetylcholinesteraseAcuteAdultAffectAgeAggressive behaviorAmericanAmygdaloid structureAnimalsAnticonvulsantsAreaAtrophicBehaviorBehavioralBenzodiazepinesBody Surface AreaBody Weight ChangesBody Weight decreasedBrainBrain InjuriesBrain regionBreathingCessation of lifeChemical WeaponsChildChildhoodClinicalCognitiveCognitive deficitsCombined Modality TherapyDataDevelopmentDiazepamDrug KineticsElectroencephalographyEmotionalEventExposure toFDA approvedFemaleFunctional disorderGlutamatesHippocampus (Brain)InfantInjuryInternationalInterneuronsInvestigationKainic Acid ReceptorsKnowledgeLeadMeasuresMediatingMidazolamModelingMorbidity - disease rateMuscarinic AntagonistsMuscarinicsN-Methyl-D-Aspartate ReceptorsNamesNatureNerve DegenerationNeurologicNeurologic DeficitNeuronsPediatricsPeripheralPermeabilityPharmaceutical PreparationsPhasePhysiologicalPilocarpinePlasmaPopulationPredispositionPropertyRattusRecoveryRecurrenceResearchRespirationRoleSavingsSeizuresSkinSomanStatus EpilepticusSurvival RateSynapsesTerrorismTestingTimeToxic effectToxinWaranimal databehavior measurementcholinergiccognitive developmentcomparative efficacydensityexcitotoxicityimmature animalindexingmalemass casualtynerve agentneuron lossneuropathologyneuroprotectionpostnatalpreclinical developmentpreventreceptorresponsevaporyoung adult
项目摘要
Nerve agents are lethal chemical weapons that have been used in war and in terrorist attacks, with devastating
consequences; the possibility that they will be used again against civilians is presently very high. One of the
clinical manifestations of exposure to nerve agents is seizure activity progressing to status epilepticus (SE)
which can lead to death, or brain damage with long-term neurological and behavioral consequences. The
American Academy of Pediatrics have pointed out the reasons that children may be more vulnerable to nerve
agent toxicity; yet, there is very little information on the appropriate countermeasures to protect the pediatric
population, as data in immature animals are lacking. The FDA has approved diazepam as the anticonvulsant
treatment for nerve agent-induced SE, irrespective of the age of the victim. However, there is sufficient
evidence indicating that diazepam does not have good neuroprotective efficacy, and, in the developing brain, it
may worsen the injury induced by the SE. Animal data are, therefore, needed to provide knowledge on how to
protect the immature brain from damage in the event of nerve agent exposure, taking into account that GABAA
receptor-mediated activity can be excitatory in the developing brain, while glutamatergic activity and
particularly the activity of NMDA receptors, which are well known for their role in excitotoxicity, is very
pronounced. We have already demonstrated the efficacy of LY293558, an AMPA/GluK1 receptor antagonist, in
stopping seizures and significantly reducing neuropathology and long-term deficits in adult rats exposed to
soman. We have also tested the combination of LY293558 with caramiphen, an antimuscarinic with NMDA
receptor antagonistic properties, and found that it terminates soman-induced seizures faster than LY293558
alone, provides full protection from neuronal damage in all brain regions examined, and the recovery of the
animals is swift with no weight loss. In the present application, we propose to test and compare the efficacy of
LY293558+caramiphen with that of LY293558 alone, and with two benzodiazepines, diazepam and
midazolam, against soman, in male and female rats of postnatal age 7, 12, and 21 days; anticonvulsant
treatments will be administered 1 h after soman exposure. We hypothesize that LY293558+caramiphen will
provide more benefits than LY293558 alone, and will prove to be far superior to both diazepam and midazolam
in stopping soman-induced seizures, preventing neuronal degeneration, neuronal loss, GABAergic
interneuronal loss, atrophy and pathophysiological alterations in the amygdala and hippocampus, as well as
cognitive, behavioral, and neurological deficits studied up to 6 months postexposure. The data acquired will
contribute immensely in developing safe and efficacious countermeasures for protecting the lives of infants and
children and prevent long-term morbidities.
神经毒剂是在战争和恐怖袭击中使用的致命化学武器,具有毁灭性
后果;它们再次被用来对付平民的可能性目前很高。其中一个
暴露于神经毒剂的临床表现是癫痫活动进展到癫痫持续状态(SE)
这可能会导致死亡或脑损伤,并产生长期的神经和行为后果。这个
美国儿科学会指出了儿童可能更容易受到神经影响的原因
毒物毒性;然而,关于保护儿童的适当对策的信息很少。
人口,因为缺乏关于未成熟动物的数据。FDA已批准安定作为抗惊厥药物
治疗神经毒剂诱发的SE,无论受害者的年龄。然而,有足够的
证据表明,安定没有良好的神经保护效果,在发育中的大脑中,它
可能会加重SE造成的损伤。因此,需要动物数据来提供关于如何
在神经毒剂暴露的情况下保护未成熟的大脑免受损害,考虑到GABAA
受体介导的活性在发育中的大脑中是兴奋的,而谷氨酸能活性和
尤其是nmda受体的活性,它们在兴奋性毒性中的作用是众所周知的,
已经宣布了。我们已经证明了AMPA/GluK1受体拮抗剂LY293558在
染毒成年大鼠停止癫痫发作并显著降低神经病理学和长期功能缺陷
索曼。我们还测试了LY293558与卡米芬的联合用药,卡米芬是一种与NMDA一起使用的抗霉菌药物
受体拮抗特性,并发现它比LY293558更快地终止梭曼诱导的癫痫发作
单独使用时,可在所检查的所有脑区提供全面的保护,防止神经元损伤,并可恢复
动物跑得很快,体重没有减轻。在目前的应用中,我们建议测试和比较
LY293558+卡拉米芬与LY293558单用,并与两种苯二氮卓类药物安定和
咪达唑仑对出生后7、12和21天的雄性和雌性大鼠的抗梭曼作用;抗惊厥药
治疗将在接触梭曼1小时后进行。我们假设LY293558+卡拉米芬会
提供比LY293558更多的好处,并将被证明远远优于安定和咪达唑仑
在阻止梭曼诱导的癫痫发作,防止神经元变性,神经元丢失,GABA能
杏仁核和海马区的神经元间丢失、萎缩和病理生理改变,以及
对暴露后6个月的认知、行为和神经缺陷进行了研究。所获得的数据将
为制定安全有效的婴儿和儿童生命保护对策作出巨大贡献
儿童和预防长期疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Maria F. Braga其他文献
Maria F. Braga的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Maria F. Braga', 18)}}的其他基金
Antiglutamatergic Therapy to Protect the Brain Against Nerve Agents
抗谷氨酸治疗可保护大脑免受神经毒剂的侵害
- 批准号:
10685433 - 财政年份:2022
- 资助金额:
$ 44.96万 - 项目类别:
Targeting the Glutamatergic System to Counteract Soman Toxicity in Immature Rats
针对未成熟大鼠的谷氨酸能系统抵消梭曼毒性
- 批准号:
9002644 - 财政年份:2015
- 资助金额:
$ 44.96万 - 项目类别:
Efficacy of GluR5 Antogonists Against Soman-Induced Seizures and Neuropathology
GluR5 拮抗剂对梭曼诱发的癫痫发作和神经病理学的功效
- 批准号:
8526578 - 财政年份:2006
- 资助金额:
$ 44.96万 - 项目类别:
Efficacy of GluR5 Antogonists Against Soman-Induced Seizures and Neuropathology
GluR5 拮抗剂对梭曼诱发的癫痫发作和神经病理学的功效
- 批准号:
7224647 - 财政年份:2006
- 资助金额:
$ 44.96万 - 项目类别:
Efficacy of GluR5 Antogonists Against Soman-Induced Seizures and Neuropathology
GluR5 拮抗剂对梭曼诱发的癫痫发作和神经病理学的功效
- 批准号:
7294293 - 财政年份:2006
- 资助金额:
$ 44.96万 - 项目类别:
Efficacy of GluR5 Antogonists Against Soman-Induced Seizures and Neuropathology
GluR5 拮抗剂对梭曼诱发的癫痫发作和神经病理学的功效
- 批准号:
8732707 - 财政年份:2006
- 资助金额:
$ 44.96万 - 项目类别:
Efficacy of GluR5 Antogonists Against Soman-Induced Seizures and Neuropathology
GluR5 拮抗剂对梭曼诱发的癫痫发作和神经病理学的功效
- 批准号:
7496079 - 财政年份:2006
- 资助金额:
$ 44.96万 - 项目类别:
Efficacy of GluR5 Antogonists Against Soman-Induced Seizures and Neuropathology
GluR5 拮抗剂对梭曼诱发的癫痫发作和神经病理学的功效
- 批准号:
8145354 - 财政年份:2006
- 资助金额:
$ 44.96万 - 项目类别:
Efficacy of GluR5 Antogonists Against Soman-Induced Seizures and Neuropathology
GluR5 拮抗剂对梭曼诱发的癫痫发作和神经病理学的功效
- 批准号:
7681582 - 财政年份:2006
- 资助金额:
$ 44.96万 - 项目类别:
Efficacy of GluR5 Antogonists Against Soman-Induced Seizures and Neuropathology
GluR5 拮抗剂对梭曼诱发的癫痫发作和神经病理学的功效
- 批准号:
8333960 - 财政年份:2006
- 资助金额:
$ 44.96万 - 项目类别:
相似海外基金
The European Hydrogen Academy (HyAcademy.EU)
欧洲氢学院 (HyAcademy.EU)
- 批准号:
10110448 - 财政年份:2024
- 资助金额:
$ 44.96万 - 项目类别:
EU-Funded
REU Site: Summer Academy in Sustainable Manufacturing
REU 网站:可持续制造夏季学院
- 批准号:
2348993 - 财政年份:2024
- 资助金额:
$ 44.96万 - 项目类别:
Standard Grant
GP-UP Ocean Research College Academy Engagement in Authentic Geoscience Learning Ecosystems (ORCA-EAGLE)
GP-UP 海洋研究学院学院参与真实的地球科学学习生态系统 (ORCA-EAGLE)
- 批准号:
2326962 - 财政年份:2024
- 资助金额:
$ 44.96万 - 项目类别:
Standard Grant
HyAcademy.EU: The European Hydrogen Academy
HyAcademy.EU:欧洲氢学院
- 批准号:
10101978 - 财政年份:2024
- 资助金额:
$ 44.96万 - 项目类别:
EU-Funded
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
- 批准号:
498310 - 财政年份:2024
- 资助金额:
$ 44.96万 - 项目类别:
Operating Grants
Conference: Cyberinfrastructure Leadership Academy: Team Science and Grand Challenges
会议:网络基础设施领导学院:团队科学和重大挑战
- 批准号:
2414440 - 财政年份:2024
- 资助金额:
$ 44.96万 - 项目类别:
Standard Grant
Travel: NSF Student Travel Grant for 2024 Academy of Management Annual Meeting (AOM)
旅行:2024 年管理学院年会 (AOM) 的 NSF 学生旅行补助金
- 批准号:
2420866 - 财政年份:2024
- 资助金额:
$ 44.96万 - 项目类别:
Standard Grant
Semiconductor Higher Technical Skills Academy Wales: Recruitment, Retention & Upskilling
威尔士半导体高等技术技能学院:招聘、保留
- 批准号:
10076049 - 财政年份:2023
- 资助金额:
$ 44.96万 - 项目类别:
Collaborative R&D
Simulation Academy at Yale: Youth Entering Science (SAY-YES!)
耶鲁大学模拟学院:青年进入科学(说是!)
- 批准号:
10663646 - 财政年份:2023
- 资助金额:
$ 44.96万 - 项目类别:
Collaborative Research: GP-GO: Climate Leaders Academy: a professional development opportunity in the geosciences
合作研究:GP-GO:气候领袖学院:地球科学领域的专业发展机会
- 批准号:
2232215 - 财政年份:2023
- 资助金额:
$ 44.96万 - 项目类别:
Continuing Grant














{{item.name}}会员




